Pharsight

Xeljanz patents expiration

XELJANZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7265221 PF PRISM CV Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7301023 PF PRISM CV Chiral salt resolution
Dec, 2020

(3 years ago)

US6965027 PF PRISM CV Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 27 days ago)

USRE41783 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(1 year, 7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7842699 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2020

(3 years ago)

US7091208 PF PRISM CV Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2020

(3 years ago)

US6956041 PF PRISM CV Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

Xeljanz is owned by Pf Prism Cv.

Xeljanz contains Tofacitinib Citrate.

Xeljanz has a total of 7 drug patents out of which 6 drug patents have expired.

Expired drug patents of Xeljanz are:

  • US7842699
  • US7091208
  • US6956041
  • US7265221
  • US7301023
  • US6965027

Xeljanz was authorised for market use on 06 November, 2012.

Xeljanz is available in tablet;oral dosage forms.

Xeljanz can be used as treatment of adult patients with moderately to severely active ulcerative colitis (uc), treatment of rheumatoid arthritis.

Drug patent challenges can be filed against Xeljanz from 06 November, 2016.

The generics of Xeljanz are possible to be released after 08 December, 2025.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Patient Population(NPP) Sep 25, 2023
New Indication(I-761) Dec 14, 2020
M(M-135) Feb 21, 2017
New Indication(I-780) May 30, 2021
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 06 November, 2012

Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis

Dosage: TABLET;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(1 year, 7 months from now)

Xeljanz is owned by Pfizer.

Xeljanz contains Tofacitinib Citrate.

Xeljanz has a total of 1 drug patent out of which 0 drug patents have expired.

Xeljanz was authorised for market use on 25 September, 2020.

Xeljanz is available in solution;oral dosage forms.

The generics of Xeljanz are possible to be released after 08 December, 2025.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 25, 2023

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 25 September, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents